The silent disease emerging as major public health concern

Medical experts are raising concerns over the growing incidence of silent kidney cancer, specifically renal cell carcinoma (RCC), which accounts for nearly 90% of all kidney cancer cases globally. The disease, which originates in microscopic tubules of the kidneys, affects men twice as often as women and results in over 430,000 new cases and 175,000 deaths annually. While less common in India compared to breast or lung cancer, RCC is rising steadily in urban areas. Known as a silent cancer, RCC often presents no symptoms until it reaches an advanced stage, making early detection challenging. Key risk factors include obesity, which creates chronic inflammation, tobacco smoking, and hypertension, which damages renal tissue. Genetic conditions like Von Hippel-Lindau syndrome also increase susceptibility. Many cases are discovered incidentally through routine scans for unrelated health issues, improving early intervention rates. Treatment options for RCC have advanced significantly, with surgical removal remaining the primary approach for early-stage disease. Precision medicine has introduced targeted therapies that block molecular pathways driving tumor growth, while adjuvant immunotherapy helps the immune system destroy cancer cells, extending disease-free survival for high-risk patients. Despite these medical advancements, public awareness remains low, with no population-wide screening programs in place. Preventative measures, such as addressing obesity, reducing tobacco use, and managing hypertension, are critical to reducing the disease burden. World Kidney Cancer Day 2026, observed on the third Thursday of June, will focus on Kidney Cancer and Emotional Wellbeing to highlight the psychological impact on patients. Enhanced awareness, healthier lifestyles, and early detection are emphasized as the most effective tools against this silent disease.